Dr LI Peng    
李鹏

0000-0003-4530-2400

Biography

Dr. Peng LI obtained his PhD in University of Cambridge, Bachelor degree in Tsinghua University. He is currently a Visiting Professor in department of Surgery and a principal investigator at Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences. He is a member of AACR (American Association for Cancer Research) and ASH (American Society of Hematology). Dr. Li obtained multiple national grants, including NSFC Excellent Young Scientists Fund, NSFC Key International Collaboration Fund, and MOST National Key Research and Development Plan. He serves as the vice-president of Guangdong Society for Immunology.

Dr. Li's research mainly focuses on development of new cellular immunotherapies for treating cancer. He is committed to optimize the designs of chimeric antigen receptor (CAR) vectors, study mechanisms underlying the reprogramming from T cells to ITNKs, and establish the pre-clinical drug efficacy evaluation platform for cancer immunotherapy. In collaboration with multiple clinical teams in China and New Zealand, CAR-T and ITNK cell therapies for hematopoietic malignancies and solid tumors developed by Dr. Li's team have been evaluated in clinical trials. These studies not only supply new ideas for developing next-generation genetic engineered T cells but also provide scientific principles guiding the clinical trials of CAR-T cell therapy. In the last five years, Peng Li has published over 40 research articles.

Research Interests

• CAR-T cell
• Reprogram from T cells to ITNKs
• Humanized mouse models

Selected Publications

1. Qin L, Cui Y, Yuan T, Chen D, Zhao R, Li S, Jiang Z, Wu Q, Long Y, Wang S, Tang Z, Pan H, Li X, Wei W, Yang J, Luo X, Zhang Z, Tang Q, Liu P, Weinkove R, Yao Y, Qin D, Thiery JP*, Li P*. Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis. Nat Commun. 2022 Oct 13;13(1):6051.
2. Jiang Z#, Cheng L#, Wu Z, Zhou L, Hong Q, Wu Q, Long Y, Huang Y, Xu G, Yao Y, Tang C, Zhang Z, Yang L, Luo W, Yang J, Gong L, Liu P, Chen X, Cui S, Zhang Q, Li Y*, Li P*. Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors. EMBO Rep. 2022 Jun 7;23(6):e54275.
3. Jiang Z#, Qin L#, Tang Y#, Liao R, Shi J, He B, Li S, Zheng D, Cui Y, Wu Q, Long Y, Yao Y, Wei Z, Hong Q, Wu Y, Mai Y, Gou S, Li X, Weinkove R, Norton S, Luo W, Feng W, Zhou H, Liu Q, Chen J, Lai L, Chen X, Pei D, Graf T, Liu X, Li Y, Liu P*, Zhang Z*, Li P*. Human induced-T-to-natural killer cells have potent anti-tumour activities. Biomark Res. 2022 Mar 24;10(1):13.
4. Pang Z#. Shi J#, Qin L#, Chen A#, Tang Y, Yang H, Huang Y, Wu Q, Li X, He B, Li T, Liang B, Zhang J, Gao B, Liu M, Feng Y, Ye X, Chen X, Wang L, Yu Tian1, Hao Li1, Li J, Hu H, He J, Hu Y, Zhi C, Tang Z, Gong Y, Xu F, Xu L, Fan W, Zhao M, Chen D, Lian H*, Yang L*, Li P*, Zhang Z*. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol. 2021 Jul 29;14(1):118.
5. Jiang Z#, Liao R#, Lv J#, Li S, Zheng D, Qin L, Wu D, Chen S, Long Y, Wu Q, Wang S, Lin S, Huang X, Tang Z, Shi P, Zhou H, Liu Q, Zhao R, Li Y, Jie Y, Wei W, Lai P, Du X, Cui S, Weinkove R, Liu P, Pei D, Yao Y*, Li P*. IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. Leukemia. 2021 May;35(5):1380-1391.
6. Lai Y#, Weng# J, Wei X, Qin L, Lai P, Zhao R, Jiang Z, Li B, Lin S, Wang S, Wu Q, Tang C, liu P, Pei D, Yao Y, Du* X, and Li* P. Toll-like Receptor 2 Costimulation Potentiates the Antitumor Efficacy of CAR T Cells. Leukemia. 2017 Aug 3.
7. Lv J#, Zhao R#, Wu D#, Zheng D, Wu Z, Shi J, Wei X, Wu Q, Long Y, Lin S, Wang S, Wang Z, Li Y, Chen Y, He Q, Chen S, Yao H, Liu Z, Tang Z, Yao Y, Pei D, Liu P, Zhang X, Zhang Z, Cui S, Chen R, Li P*. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. J Hematol Oncol. 2019 Feb 18;12(1):18.
8. Lin S#, Huang G#, Cheng L#, Li Z, Xiao Y, Deng Q, Jiang Y, Li B, Lin S, Wang S, Wu Q, Yao H, Cao S, Li Y, Liu P, Wei W, Pei D, Yao Y, Wen Z, Zhang X, Wu Y, Zhang Z, Cui S, Sun X, Qian X*, Li P*. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. MAbs. 2018 Oct 02. 10:8:1301-1311.
9. Xiao Y, Jiang Z, Li Y, Ye W, Jia B, Zhang M, Xu Y, Wu D, Lai L, Chen Y, Chang Y, Huang X, Liu H, Qing G, Liu P, Li Y, Xu B, Zhong M, Yao Y, Pei D, Li P*. ANGPTL7 regulates the expansion and repopulation of human hematopoietic stem and progenitor cells. Haematologica. 2015 May;100(5):585-94.
10. Li P, Burke S et al, Liu P*. Reprogramming of T Cells to Natural Killer-Like Cells upon Bcl11b Deletion. Science. 2010 Jul 2;329(5987):85-9.